Use of Single-Arm Trials for US Food and Drug Administration Drug Approval in Oncology, 2002-2021

FDA Approves Zanubrutinib for CLL or SLL

FDA Approves Updated Drug Labeling for Capecitabine Tablets Under Project Renewal

FDA Approves New Dosing Regimen for Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn

Adcetris Approved for Pediatric Patients With High Risk Classical Hodgkin Lymphoma

FDA Approves Tremelimumab in Combination With Durvalumab and Platinum-Based Chemotherapy for Metastatic NSCLC

FDA Approves Teclistamab for Patients With Relapsed/Refractory MM

FDA Approves New Immunotherapy Combo for Liver Cancer

Use of Single-Arm Trials for US Food and Drug Administration Drug Approval in Oncology, 2002-2021

header-info

Jan, 03, 2023

Single-arm trials have allowed for transformative therapies to be made available to patients expeditiously. However, using single-arm trials to support drug approval presents several challenges that must be carefully considered.